Accelagen’s Dynamic Approach to Clinical Research
In the complex world of clinical research and drug development, becoming a successful CRO hinges on the ability to adapt, innovate and consistently deliver exceptional value. For 15 years, Accelagen has not only evolved to meet the ever-changing demands of the industry, but has thrived by embracing agility, prioritising collaboration, and challenging the status quo.
Staying Ahead in an Evolving Industry
Clinical research, like every industry, has witnessed significant changes over the past 15 years, from economic downturns to the COVID-19 pandemic. At Accelagen, we’ve consistently demonstrated our ability to adapt quickly to these changes by prioritising an agile approach, working efficiently to overcome obstacles and deliver high-quality results for our clients. This commitment has allowed us to swiftly adjust to the evolving landscape of clinical research.
With agility as a core value, Accelagen was able to navigate the challenges of COVID-19 with minimal disruption to our activities. We have always empowered our team to work in a way that best suits their lives, focusing on our ability to drive meaningful outcomes while allowing them to manage their work according to their individual needs. This meant that we had already embraced remote management and minimised travel, so transitioning to a COVID-19 work environment was a seamless extension of our existing practices.
While things evolve and the industry changes, the most important element for us is to never compromise on quality. Our commitment to exceeding the expectations of our clients is what has helped us develop long-term partnerships.
More Than a Transactional CRO
At Accelagen, we aim to provide more than the standard CRO services; we strive to deliver high-quality results, add tangible value, and help our clients bring innovative medicines and technologies to patients.
We have worked hard to recruit a talented team and develop the most efficient processes. However, we don’t settle for the status quo. Instead, we continuously seek ways to improve our processes and add value without compromising quality or increasing costs. We like to call this “positive disruption”, and we believe this is how we can continue to deliver exceptional value to our clients. It is also this basic philosophy of how we can use data to tell a compelling story—not just today, but well into the future—that helps us stand out.
A Holistic Approach to Clinical Research
Another key differentiator for Accelagen is our integrated approach to research, offering both clinical and regulatory development services. While many mid-sized CROs specialise in one or the other, we recognise that these are inherently harmonious disciplines. We encourage our clients to think about their end game and define their ultimate goal, and then we work backwards to develop a comprehensive strategic plan. By combining clinical and regulatory expertise, we can guide our clients towards their desired outcomes efficiently and with the highest quality results. This forward-looking and holistic approach ensures our clients are set up for lasting success.
Australia as a Growing Research Hub
Australia is one of the fastest-growing clinical trial markets, making it an attractive destination for foreign sponsors. There are three key aspects that drive this growth:
- Speed: Australia offers a very efficient but pragmatic regulatory system, allowing faster study start-up times. This advantage allows sponsors to enter the clinic sooner, accelerating the development process.
- Quality: In addition to the speed to start-up, Australia has a world-leading healthcare system. Our regulatory system adheres to ICH guidelines, ensuring that the data coming out of Australia is of the highest quality and is readily accepted for regulatory submissions worldwide, from IND applications to the FDA or MAA submissions in Europe. This simplifies the process of global regulatory submissions.
- Cost: Despite fluctuations in currency exchange rates, the Australian dollar offers a cost-effective advantage for sponsors from the US and Europe. Furthermore, the Australian government provides generous R&D tax incentives, which increases this cost-benefit even further. Together, this provides immense financial benefits for foreign sponsors looking to conduct clinical trials in Australia.
At Accelagen, we think it’s important to keep all our expertise and activities in Australia. While many CROs will outsource some services, we maintain a local focus to maximise our clients’ access to the R&D tax incentives and ensure the integrity of our services. This provides a significant advantage for our clients.
A Commitment to Our Core Values
As the company has continued to evolve over the past 15 years, we have never strayed from our core values. We remain dedicated to our agility, committed to delivering high-value results, and passionate about making a difference in the future of human health.
With a continued commitment to our clients and patients around the world, we look forward to a new chapter of medical innovation. Check out our next article to learn what’s in store for 2025 and beyond at Accelagen.
For more information or to discuss your regulatory submission needs, contact us today!